Teleflex Archives - Page 4 of 5 - Medical Design Sourcing

The best places to work for medtech sales reps in 2022

Teleflex (NYSE:TFX), ConMed (NSDQ:CNMD) and Medtronic (NYSE:MDT) topped the list of best places to work in medtech sales in 2022, according to a MedReps.com survey of medical sales representatives.

The 11th annual MedReps survey polled over 2,300 MedReps professionals to determine which medtech sales companies are most sought-after in the industry.

Overall, pay and leadership were the most important considerations in an employer, followed closely by culture, according to the survey.

“Given the continued challenges medical sales reps faced in 2021, valuing leadership and culture in their place of work isn’t a surprise – and it’s important to recognize employers, like these companies on this list, that are doing much to support their employees,” MedReps CEO Josh Goodwin said in a news release. “We’re thrilled to highlight deserving employers to our community of medical sales professionals.”

Diversity, equity, inclusion and belonging was ranked as im…

Teleflex beats The Street in Q3 but warns of COVID-19 headwinds

Teleflex (NYSE: TFX) today reported third-quarter results that beat the consensus forecast on Wall Street but lowered its full-year revenue guidance as the COVID-19 pandemic affects sales across product lines.

The Wayne, Pennsylvania–based critical care and surgical tech company reported profits of $199.2 million, or $4.20 per share, on sales of $700.3 million for the three months ended September 26, 2021, nearly doubling the bottom line on sales growth of 11.5% compared with Q2 2020.

Adjusted to exclude one-time items, earnings per share were $3.51, 48¢ ahead of The Street, where analysts were looking EPS of $3.03 on sales of $698.26 million.

“Teleflex delivered solid third-quarter results reflecting the benefits of our diversified product portfolio and disciplined operating execution, despite varying levels of headwinds associated with COVID-19 infections across our product lines and geographic segments,” CEO Liam Kelly said in a news relea…

Teleflex raises guidance on respiratory sale headwinds, beats Street in Q2

Teleflex (NYSE:TFX) posted Street-beating second-quarter financial results and increased its guidance for the full year.

The Wayne, Pa.-based company posted profits of $83.2 million, or $1.76 per share, on sales of $713.5 million for the three months ended June 27, 2021, increasing its bottom-line by more than six times year-over-year on sales growth of 25.8%.

Adjusted to exclude one-time items, earnings per share were $3.35, 48¢ ahead of Wall Street, where analysts were looking for sales of $685.9 million.

“Although we continue to see varying levels of recovery across our product lines and geographic segments from challenges due to COVID-19, our second-quarter results showed continued positive business momentum,” Teleflex chairman, president & CEO Liam Kelly said in a news release. Based on the strength of our first-half results and our outlook for the remainder of the year, we are maintaining our 2021 constant currency revenue guidance range …

MedTech 100 roundup: New all-time best reached

Once again, the medtech industry has soared to new heights, eclipsing its all-time best performance by the tiniest of margins.

MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week (July 2) at 114.59 points, coming in just 0.01 points ahead of the 114.58-point mark set in April — previously the industry’s all-time best performance.

The new high mark also represents a 1% rise from the 113.42-point total reached last week (June 25). The industry took a strong June into July, rising nearly 7% over the past four weeks.

Having overcome some recent setbacks, medtech’s performance continues to reflect an overall rebound from the struggles brought on by the COVID-19 pandemic, too. The industry has registered a 24.1% rise from the pre-pandemic high of 92.32 (set on Feb. 19, 2020), plus an 84.4% increase from the mid-pandemic low of 62.13 (March 23, 2020).

The positive movement in medtech …

Teleflex completes respiratory asset sale to Medline

Teleflex (NYSE:TFX) announced that it completed the divestiture of a significant portion of its respiratory business to Medline Industries.

Wayne, Pa.-based Teleflex announced last month that it agreed to sell a significant portion of its respiratory business to Medline for $286 million, reduced by $12 million of working capital to be retained by Teleflex. The respiratory product lines being divested to Medline include Teleflex’s Hudson RCI products oxygen and aerosol therapy, active humidification, non-invasive ventilation and incentive spirometers, which together generated $139 million in revenue in 2020.

The company expected the divested respiratory product lines to contribute net revenue equal to the previous year’s $139 million for 2021. Teleflex expects 2021 headwinds for revenues between $28 million and $32 million and adjusted EPS between 10¢ per share and 15¢ per share. The company maintains its current 2021 adjusted EPS guidance range, hav…

DTW Podcast: How AtriCure built a big business in Afib; A deep look into Abbott’s new Coronary imaging platform

In this week’s episode of the DeviceTalks Weekly Podcast, Dr. Nick West, CMO & divisional VP of global medical affairs at Abbott’s vascular business, discusses the European launch of the company’s new coronary imaging platform.

Dr. West explains how the AI-powered platform works and the benefits it offers for decision-making during coronary stenting procedures. He also delves into the AI-based technology behind the platform and the direction both imaging and medtech as a whole are heading with AI.

In our second interview, Mike Carrel, CEO and president of AtriCure, explains how the company became a force focusing on the atrial fibrillation (Afib) and left atrial appendage (LAA) markets.

Carrel walks listeners through the company’s efforts to expand its reach into the connected pain management market. But then he makes a strong case building out its Afib pipeline which includes the EPi-Sense System, which in April received FDA approval to treat …

DTW Podcast: How AtriCure built a big business in Afib; A deep look into Abbott’s new Coronary imaging platform

In this week’s episode of the DeviceTalks Weekly Podcast, Dr. Nick West, CMO & divisional VP of global medical affairs at Abbott’s vascular business, discusses the European launch of the company’s new coronary imaging platform.

Dr. West explains how the AI-powered platform works and the benefits it offers for decision-making during coronary stenting procedures. He also delves into the AI-based technology behind the platform and the direction both imaging and medtech as a whole are heading with AI.

In our second interview, Mike Carrel, CEO and president of AtriCure, explains how the company became a force focusing on the atrial fibrillation (Afib) and left atrial appendage (LAA) markets.

Carrel walks listeners through the company’s efforts to expand its reach into the connected pain management market. But then he makes a strong case building out its Afib pipeline which includes the EPi-Sense System, which in April received FDA approval to treat…

MedTech 100 roundup: Turnaround for the industry?

A turgid month for the medtech industry might be drifting into the past after the past week indicated a slight turnaround as summer nears.

MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week at 107.74 points, marking a 1.4% rise from the 106.22-point mark set one week prior.

Having endured its largest slide of 2021 in recent weeks, the index is already demonstrating signs of a rebound after April brought the industry’s all-time best performance.

Despite the setbacks that have plagued the industry over the past month or so, medtech’s performance continues to reflect a rebound from the struggles brought on by the COVID-19 pandemic. Overall, it has registered a 16.7% rise from the pre-pandemic high of 92.32 (set on Feb. 19, 2020), plus a 73.4% increase from the mid-pandemic low of 62.13 (March 23, 2020).

The overall markets were on the opposite end of the spectrum over the p…

Teleflex selling some respiratory assets to Medline

Teleflex (NYSE:TFX) announced today that it agreed to sell a significant portion of its respiratory business to Medline Industries for $286 million.

Total consideration for the sale amounts to $286 million, reduced by $12 million of working capital to be retained by Teleflex, according to a news release. Assets set to be divested generated revenues of $139 million in 2020, while Teleflex expects 2021 headwinds for revenues between $28 million and $32 million and adjusted EPS between 10¢ per share and 15¢ per share. The company maintains its current 2021 adjusted EPS guidance range, having announced restructuring plans in last month’s first-quarter earnings report.

Wayne, Pa.-based Teleflex’s respiratory product lines being divested to Medline include its oxygen and aerosol therapy, active humidification, non-invasive ventilation and incentive spirometers. The companies expect the acquisition to close in the third quarter of 2021.

Teleflex pla…

Teleflex’s announces Street-beating Q1, restructuring plans

Teleflex (NYSE:TFX) today posted first-quarter results that beat the Wall Street consensus forecast and announced business streamlining plans for 2021.

The Wayne, Pa.–based maker of critical care and surgical products reported earnings of $74.9 million, or $1.58 per share, off sales of $633.9 million for the quarter ended March 31, 2021, for a –43% bottom-line drop on top-line growth of 0.5%.

Adjusted to exclude one-time items, earnings per share were $2.87, 45¢ ahead of The Street, where analysts were looking EPS of $2.42 on sales of $626.25 million.

“The first quarter of 2021 was a strong start to the year for Teleflex, one in which we exceeded our expectations for revenue, led by the performance of the Americas and Asia,” Teleflex CEO Liam Kelly said in a news release.

“In addition to strong first-quarter top-line performance, we generated the highest adjusted gross and operating margins since becoming a pure-play medical device com…

4 catheter-based devices to watch for in 2021

Medical device companies are working to gain regulatory approvals and launch new catheter-based devices as the world slowly returns to normal after reeling from the COVID-19 pandemic.

As of April 19, the FDA had approved 11 medical devices this year — two of them catheter-based. In comparison, the regulatory agency approved 19 devices by April 19 last year. However, none of those devices was catheter-based.

Research and development spending at some of the world’s biggest medical device companies in the world was up 0.9% in the last year, according to a recent Medical Design & Outsourcing analysis. The medical device pipeline for 2021 is full of innovations. Here are four companies with catheter-based devices that are expected to launch or gain regulatory approval in the next year.

Next >>

4 catheter-based devices to watch for in 2021

Medical device companies are working to gain regulatory approvals and launch new catheter-based devices as the world slowly returns to normal after reeling from the COVID-19 pandemic.

As of April 19, the FDA had approved 11 medical devices this year — two of them catheter-based. In comparison, the regulatory agency approved 19 devices by April 19 last year. However, none of those devices was catheter-based.

Research and development spending at some of the world’s biggest medical device companies in the world was up 0.9% in the last year, according to a recent Medical Design & Outsourcing analysis. The medical device pipeline for 2021 is full of innovations. Here are four companies with catheter-based devices that are expected to launch or gain regulatory approval in the next year.

Next >>